Peptides: The Good, the Bad, and the Sketchy

The wellness internet has moved from powders and wearables into something more clinical: peptides, GLP-1s, retatrutide, BPC-157, GHK-Cu, thymosin, epithalon, and a growing list of compounds that sound less like a recovery routine and more like a lab order.

Huberman just devoted nearly three hours to the science, uses, sourcing, and safety questions. GQ is covering why fitness circles are already buzzing about retatrutide, a not-yet-approved weight-loss peptide being framed as the next major escalation after Ozempic and tirzepatide. Longevity clinics are talking about peptides for sleep, skin, immune function, tissue repair, metabolism, and aging. The conversation has clearly moved beyond niche biohacker forums.

There are good reasons for the attention. Peptides are real biological signals, and some of them already sit inside serious medicine. Others are showing early promise that could eventually matter for metabolic health, obesity care, tissue repair, inflammation, immune function, skin, sleep, and longevity. But that same promise is what makes the current free-for-all risky. The category now includes prescribed medications, experimental compounds, gray-market injectables, mislabeled research chemicals, and social-media protocols delivered with a level of certainty the evidence has not earned.

Inside Plunge, co-founder Ryan Duey has been looking at the category from firsthand experience rather than hype alone. After experimenting with peptides for the better part of three to four years, his takeaway is practical: some compounds did very little, some were noticeably useful, and the ones worth discussing were only useful when paired with clear goals, bloodwork, body-composition tracking, and a willingness to admit when the payoff was not worth the cost.

The better question is not whether peptides are a breakthrough or a scam. It is where the upside is real, where the evidence is still early, and where the risk stops being sophisticated and starts looking like ordering mystery freezer confetti from a no-name lab in China because a shirtless guy with a ring light said his shoulder felt amazing.

What Peptides Actually Are

Peptides are short chains of amino acids. Proteins are made from amino acids too, but peptides are smaller and can function as targeted signals in the body. Depending on the peptide, that signal might relate to appetite, glucose regulation, skin, immune activity, tissue repair, hormones, or other systems.

That signaling role is why the field has become so interesting. If a molecule can tell the body to change appetite, heal tissue, modulate inflammation, or adjust metabolic behavior, it is not hard to see why clinicians, athletes, longevity obsessives, and the entire optimization economy would start paying attention.

Huberman Lab's recent episode, Peptides: The Science, Uses & Safety, is useful because it refuses to treat peptides as one magic category. Dr. Abud Bakri and Huberman discuss BPC-157, GHK-Cu, pinealon, epithalon, thymosin alpha-1, GLP-1s, retatrutide, melanotan, growth-hormone-promoting peptides, sourcing, legality, safety, and the gap between animal and human data.

One of the stranger origin stories is BPC-157. In the episode notes, Bakri traces the story back to Ivan Pavlov, who was not just making dogs salivate for textbook clout; he was also selling dog gastric juice as a medical product for GI distress and wound healing. Decades later, a Croatian group isolated BPC-157 as a 15-amino-acid fragment from a much larger gut protein, which is how a stomach-protection idea eventually wandered into bodybuilding forums as a tendon-and-recovery obsession.

That distinction matters. A prescribed GLP-1 medication, a topical copper peptide, an experimental longevity compound, and a vial from a gray-market website do not belong in the same mental drawer simply because they share a word.

The Upside Is Big Enough to Take Seriously

GLP-1 medications changed the obesity and diabetes conversation because they did something most weight-loss advice never could: they worked in a measurable, medically meaningful way for many patients. By mimicking a hormone involved in appetite, satiety, blood sugar, and digestion, drugs like semaglutide helped move obesity care away from moralizing and toward biology.

Then came dual-agonist drugs like tirzepatide. Now retatrutide is pushing the conversation again. In GQ's piece on why fitness circles are buzzing about retatrutide, physicians describe it as a triple-agonist drug targeting GLP-1, GIP, and glucagon receptors. GQ reports that clinical trial data has shown major weight-loss potential, with experts discussing total body-weight reductions in the 22% to 29% range.

Ryan Duey's Peptide Experience

Ryan's experience tracks with the broader point: peptides are not one thing, and the right question is not “do they work?” so much as “for what, at what dose, under what supervision, and measured against which outcome?” Retatrutide stood out to him on metabolism and glucose regulation. BPC-157 made more sense around acute injury and rehab than as an everyday maintenance habit. Copper peptides were the quieter cosmetic win.

“Retatrutide had the most significant impact for me, but not only because of weight. The more exciting part was seeing blood glucose regulation improve. I stayed on the lower end of the dosing range, tracked DEXA and bloodwork before and after, and treated it like data instead of a guessing game.”
— Ryan Duey, Plunge co-founder

The Huberman/Bakri episode is useful because it gives readers a map of the peptide world instead of one big bucket of acronyms. GLP-1s are the familiar doorway, but the conversation quickly moves into compounds with very different evidence, mechanisms, and risk profiles.

BPC-157 is the one that made every injured lifter and runner lean forward. Bakri explains that it started as a gut story, not a gym story: researchers were looking for a cytoprotective compound in the stomach before BPC-157 became famous online as a tissue-repair peptide. In animal models, it has been studied across tendon, ligament, burn, gut, and neurological injury contexts. That sounds incredible, which is why the caveat matters: the human data is thin, the mechanism is not fully nailed down, and Huberman says he avoids using it casually because of unanswered questions around blood-vessel growth and tumor biology.

“BPC-157 made the most sense to me when there was a specific injury or rehab goal. As a general maintenance compound, I did not find the cost-to-benefit nearly as compelling. It is the kind of thing I would time intentionally, not treat like a blanket supplement.”
— Ryan Duey, Plunge co-founder

GHK-Cu is the copper peptide in the skin-and-collagen lane. Bakri describes it as a tripeptide connected to type-one collagen fibers and tissue remodeling, which is more nuanced than “more collagen equals better skin.” Healthy remodeling requires both building and breaking down collagen; otherwise, you are not repairing tissue so much as making scar tissue with better branding. The skin data appears stronger than the hair-growth hype, and Bakri gives one oddly practical tell: if a topical GHK-Cu product is not blue, the copper has likely fallen out of the complex.

“Copper peptides were the sleeper for me. They weren’t the loudest thing in the peptide conversation, but they were one of the few where I could actually see a consistent cosmetic difference in my skin.”
— Ryan Duey, Plunge co-founder

Thymosin alpha-1 is more immune-system coded. The thymus is large in infancy and gradually shrinks through adulthood, and Bakri points to research connecting stronger thymic signals with better health outcomes. Thymosin alpha-1 is approved in some countries for immune-related uses and comes up in the episode around immune function, travel, illness exposure, and recovery. That does not make it a casual supplement; it makes it a good example of why peptides belong in a medical conversation instead of a checkout cart.

Pinealon sits in the cognitive-performance and sleep corner. Bakri traces it to Soviet-era bioregulator research, where the goal was not better mirror selfies but keeping soldiers, submariners, and astronauts functioning under extreme physiological stress. Huberman says he has used it sparingly and noticed changes in REM sleep, which is interesting, but also exactly the kind of claim that needs more than wearable screenshots and a confident podcast clip before it becomes a normal-person protocol.

Epithalon is the more longevity-coded cousin in that same Soviet bioregulator world. In the episode, it is tied to pineal function, melatonin signaling, aging research, animal data, and provocative long-term human claims that still need careful interpretation. This is the part of peptide medicine that feels both exciting and slippery: the biology is compelling, the anecdotes are memorable, and the line between promising and proven is not always where the internet wants it to be.

A balanced view leaves room for both ideas at once: peptide medicine may become extremely important, and the current consumer conversation is running ahead of what most people can safely evaluate on their own.

The Safety Problem Is Not Theoretical

Retatrutide is a useful example because the promise and the risk are arriving at the same time. GQ's reporting is clear that the drug is not approved yet, and nobody outside clinical trials should be taking it. Anyone sourcing it now is almost certainly operating outside normal approved prescription pathways.

That is not a minor technicality. Powerful drugs can involve side effects, dosing complexity, contraindications, and unknown long-term questions. The more effective a tool appears to be, the less sense it makes to treat access as the only hurdle.

Mindbodygreen's piece, Why It's Dangerous To Buy Peptides Online, makes the gray-market issue plain. Longevity physician Elizabeth Yurth, M.D., warns that peptides bought online without a prescription are often research chemicals rather than pharmaceutical-grade products. That can mean poor quality control, contamination, incorrect concentration, mislabeled ingredients, and no individualized dosing.

Her simplest red flag is also the most useful: if the peptide does not come with your name on it and specific instructions from a provider, it is probably not legitimate medical care.

Where Contrast Therapy Fits

Contrast therapy belongs in a different category than peptides. It is not a clinical intervention or a molecule with a dosing schedule; it is a repeatable protocol built around heat, cold, and recovery.

Cold exposure gives the nervous system a clear assignment: stay controlled while the environment becomes intensely uncomfortable. Breathing slows, attention narrows, and the body learns that stress can rise and fall without becoming panic. Sauna works from the other side of the same principle. Heat exposure raises skin temperature, increases heart rate, changes blood flow, and asks the body to manage thermal load.

The value is repeatability. You can set the water temperature, choose the sauna temperature, control the duration, build gradually, and track how you feel afterward. A simple starting point might be 15 to 25 minutes of sauna at a heat level you can tolerate while breathing comfortably, followed by 30 seconds to 2 minutes of cold exposure and a calm rewarm. The win is control and consistency, not suffering points.

Contrast therapy is not a replacement for medical care, and it is not a cure-all. Its strength is that it gives the body clear inputs it can understand: heat stress, cold stress, recovery, repeat.

A Better Recovery Stack

If peptides belong anywhere in your life, they belong in the clinical layer: a decision made with a qualified clinician who understands your goals, health history, medications, labs, risks, and the legal status of whatever is being considered.

The rest of the stack should be easier to understand:

Base layer: sleep, protein, hydration, strength training, walking, sunlight, and consistency.

Protocol layer: sauna, cold plunge, breathwork, mobility, zone 2, hard training, and deloads.

Tracking layer: HRV, resting heart rate, sleep trends, training load, mood, soreness, and energy. Useful signals, not tiny dictators.

Clinical layer: labs, diagnoses, prescribed medications, peptide therapy, hormone therapy, and other interventions that should involve a professional.

The possible benefits are compelling enough to take seriously. The possible dangers are serious enough that the internet should not be driving the protocol.

The Plunge Take

Peptides may become a bigger part of medicine, longevity, and performance over time. GLP-1s have already changed metabolic care. Retatrutide may become a major next chapter if the trials and regulatory process keep moving in the right direction. Other peptides may eventually earn clearer roles too.

The serious version of that future belongs with evidence, quality control, physician oversight, and actual indications. It does not belong to mystery vials, "research use only" labels with a wink, or copied protocols from someone whose main credential is dramatic lighting.

Most recovery stacks do not fail because they are missing the newest acronym. They fail because the base layer is inconsistent: sleep is short, protein is random, training is chaotic, stress has no off-ramp, the sauna becomes expensive furniture, and the cold plunge becomes a dare instead of a practice.

Start with the inputs your body can actually read: heat, cold, sleep, food, movement, repetition. Then, if a clinical tool belongs in the picture, let it enter through the front door with a qualified professional holding the clipboard.